Last reviewed · How we verify
Hemoporfin
Hemoporfin, marketed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., is a drug with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its unique mechanism of action. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Hemoporfin |
|---|---|
| Sponsor | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT (PHASE2)
- Enhanced Efficacy Through Optimization of Hemoporfin-Photodynamic Therapy Parameters in Port-Wine Stains (NA)
- Exacerbation of Erythema Following PDT in Patients With Probable Capillary Malformation-Arteriovenous Malformation Syndrome: Retrospective Analysis of Ultrasound and Clinical Characteristics.
- Retrospective Cohort Study on the Impact of PDL Treatment History on the Efficacy of HMME-PDT in Treating PWS Children
- Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain (PHASE4)
- A Pilot Study of Hemoporfin PDT in Children(2-7 Years Old) With Port-wine Stain (PHASE4)
- Effect of Pulsed Dye Laser on Photodynamic Therapy of Port-Wine Stains (NA)
- A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hemoporfin CI brief — competitive landscape report
- Hemoporfin updates RSS · CI watch RSS
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. portfolio CI